论文部分内容阅读
[目的]观察并评价奥美拉唑与替普瑞酮联合用药对胃溃疡患者疗效及安全性的影响。[方法]将249例胃良性溃疡患者随机分为两组:对照组(n=124)和观察组(n=125)。对照组患者接受奥美拉唑治疗,而观察组患者给予奥美拉唑与替普瑞酮联合治疗。随访1年,比较2组患者在复发率、临床疗效、愈合质量及不良反应等方面的差别。[结果]观察组溃疡复发率为0.80%,低于对照组的5.65%(P<0.05);观察组患者治疗总有效率为96.80%,显著高于对照组的88.71%(P<0.05);观察组的S2期获得率为63.20%,显著高于对照组的26.61%(P<0.05);观察组患者的出血发生率低于对照组,但发生腹痛、腹胀、皮疹、恶心的概率高于对照,但差异无统计学意义(P>0.05)。[结论]质子泵抑制剂奥美拉唑与胃黏膜保护剂替普瑞酮联用,与奥美拉唑单用比较,可明显提高胃良性溃疡的治愈率,减少复发率,且安全性高,不良反应少,具有临床价值。
[Objective] To observe and evaluate the effect of combination of omeprazole and teprenone on the efficacy and safety of gastric ulcer patients. [Method] 249 gastric ulcer patients were randomly divided into two groups: control group (n = 124) and observation group (n = 125). Patients in the control group received omeprazole, while patients in the observation group received omeprazole in combination with teprenone. Follow-up of 1 year, the difference between the two groups in recurrence rate, clinical efficacy, quality of healing and adverse reactions were compared. [Results] The recurrence rate of ulcer in observation group was 0.80%, which was lower than 5.65% in control group (P <0.05). The total effective rate in observation group was 96.80%, which was significantly higher than that in control group (88.71%, P <0.05). The acquisition rate of S2 in the observation group was 63.20%, which was significantly higher than that in the control group (26.61%, P <0.05). The incidence of bleeding in the observation group was lower than that of the control group, but the incidence of abdominal pain, bloating, rash and nausea Control, but the difference was not statistically significant (P> 0.05). [Conclusion] The combination of proton pump inhibitor omeprazole and gastric mucosal protective agent teprenone combined with omeprazole alone can significantly improve the cure rate of gastric benign ulcer, reduce the recurrence rate and have high safety , Less adverse reactions, with clinical value.